Search tips
Search criteria 


Logo of cdliPermissionsJournals.ASM.orgAEM ArticleJournal InfoAuthorsReviewers
Clin Diagn Lab Immunol. 1995 January; 2(1): 57–61.
PMCID: PMC170101

Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays.


Local immunological defense mechanisms in the cervicovaginal mucosa currently remain incompletely defined, especially from a quantitative point of view. Addition of an inert substance, lithium chloride (LiCl), into the washing buffer used to carry out the vaginal washing for collecting cervicovaginal secretions and measurement of its concentration with a flame absorption spectrophotometer, before and after the specimen is sampled, permits the quantification of the volume of cervicovaginal secretions collected and the approximation of the dilution factor of a soluble component introduced by the washing. Lithium, at a concentration of 10 mM, gives the best precision of measurement and has no effect on the results of the immunoassays. In a population of 27 nonpregnant women (age range, 18 to 45 years), the volume of cervicovaginal secretions collected by vaginal washing with 3 ml of LiCl-phosphate-buffered saline was 12% +/- 3.2% (mean +/- standard deviation) of the total volume and showed large interindividual variations (range, 5.6 to 18.8%); the mean dilution factor of a soluble component from the vaginal secretions was 9.9% +/- 2.8% (range, 6.3 to 18.8%). According to the date of the menstrual cycle, the mean volume of collected cervicovaginal secretions was significantly increased in the luteal phase in comparison with the follicular phase; conversely, the mean dilution factor of a soluble component was more important in the follicular than in the luteal phase. These features strengthen the need to quantify accurately the dilution factor introduced by vaginal washing when studying cervicovaginal immunity.

Full Text

The Full Text of this article is available as a PDF (577K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Belec L, Georges AJ, Steenman G, Martin PM. Antibodies to human immunodeficiency virus in vaginal secretions of heterosexual women. J Infect Dis. 1989 Sep;160(3):385–391. [PubMed]
  • Lehner T, Bergmeier LA, Panagiotidi C, Tao L, Brookes R, Klavinskis LS, Walker P, Walker J, Ward RG, Hussain L, et al. Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. Science. 1992 Nov 20;258(5086):1365–1369. [PubMed]
  • Lu XS, Bélec L, Pillot J. Anti-gp160 IgG and IgA antibodies associated with a large increase in total IgG in cervicovaginal secretions from human immunodeficiency virus type 1-infected women. J Infect Dis. 1993 May;167(5):1189–1192. [PubMed]
  • Thongcharoen P, Wasi C, Louisirirotchanakul S, Parry J, Connell J, Mortimer P. Immunoglobulin G antibody capture enzyme-linked immunosorbent assay: a versatile assay for detection of anti-human immunodeficiency virus type 1 and 2 antibodies in body fluids. J Clin Microbiol. 1992 Dec;30(12):3288–3289. [PMC free article] [PubMed]
  • Virolainen A, Mäkelä MJ, Esko E, Jero J, Alfthan G, Sundvall J, Leinonen M. New method to assess dilution of secretions for immunological and microbiological assays. J Clin Microbiol. 1993 May;31(5):1382–1384. [PMC free article] [PubMed]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)